Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr:171:289-331.
doi: 10.1016/j.addr.2021.02.001. Epub 2021 Feb 18.

Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network

Affiliations
Free article
Review

Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network

Zahari Vinarov et al. Adv Drug Deliv Rev. 2021 Apr.
Free article

Abstract

Although oral drug delivery is the preferred administration route and has been used for centuries, modern drug discovery and development pipelines challenge conventional formulation approaches and highlight the insufficient mechanistic understanding of processes critical to oral drug absorption. This review presents the opinion of UNGAP scientists on four key themes across the oral absorption landscape: (1) specific patient populations, (2) regional differences in the gastrointestinal tract, (3) advanced formulations and (4) food-drug interactions. The differences of oral absorption in pediatric and geriatric populations, the specific issues in colonic absorption, the formulation approaches for poorly water-soluble (small molecules) and poorly permeable (peptides, RNA etc.) drugs, as well as the vast realm of food effects, are some of the topics discussed in detail. The identified controversies and gaps in the current understanding of gastrointestinal absorption-related processes are used to create a roadmap for the future of oral drug absorption research.

Keywords: Advanced formulations; Amorphous solid dispersions; Food-drug interactions; In vitro tools; Lipid-based formulations; Microbiome; PBPK modeling; Regional differences; Specific patient populations.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest None.

Publication types

Substances